Department of Dermatology, University of Athens Medical School, A. Sygros Hospital, Athens, Greece.
Clin Dermatol. 2013 May-Jun;31(3):257-63. doi: 10.1016/j.clindermatol.2012.08.018.
Melanoma is οne of the most aggressive forms of skin cancer. Currently available treatments have little overall impact on survival rates of patients with advanced melanoma. Advances in the understanding of the molecular pathways related to tumor growth and metastatic spread have resulted in the development of targeted therapies designed to act on specific genes or molecules of these pathways. Newly introduced agents that target the process of angiogenesis or inhibit antiapoptotic proteins have been investigated in melanoma. Although the use of these agents as monotherapy has yielded disappointing results, their impact on survival when combined with cytotoxic chemotherapy agents is currently under investigation. Larger phase III trials are needed to clarify the optimal clinical benefit that can be expected of this class of agents.
黑色素瘤是最具侵袭性的皮肤癌之一。目前可用的治疗方法对晚期黑色素瘤患者的生存率影响甚微。对与肿瘤生长和转移扩散相关的分子途径的理解的进步，导致了靶向治疗的发展，旨在针对这些途径的特定基因或分子。已经研究了新引入的靶向血管生成过程或抑制抗凋亡蛋白的药物在黑色素瘤中的作用。虽然这些药物作为单一疗法的使用结果令人失望，但当与细胞毒性化疗药物联合使用时，它们对生存的影响目前正在研究中。需要更大规模的 III 期试验来阐明这类药物的最佳临床获益。
